Article
Further Support for the Involvement of Genetic Variants Related to the Serotonergic Pathway in the Antidepressant Response in Children and Adolescents After a 12-Month Follow-Up: Impact of the HTR2A rs7997012 Polymorphism.
Journal of child and adolescent psychopharmacology - 1 Dec 2018
Gassó Patricia, Blázquez Ana, Rodríguez Natalia, Boloc Daniel, Torres Teresa, Mas Sergi, Lafuente Amalia, Lázaro Luisa
Abstract excerpt
Objective: Fluoxetine is an effective and well-tolerated pharmacological treatment for children and adolescents with major depressive disorder (MDD). However, a high percentage of patients do not respond. There is a substantial genetic contribution to this variable clinical outcome. Based on previous genetic results of our group and given the lack of pharmacogenetics studies of antidepressant response with a long...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.